News | August 14, 2022
Nectar Lifesciences posts Q1 FY23 consolidated PAT at Rs. 3.89 Cr
The company has reported total income of Rs. 403.38 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 403.38 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 4138.6 crores during the period ended June 30, 2022.
The inspection concluded with four Form 483 observations. None of the observations were related to data integrity.
The company is focused on therapies such as skinceuticals, gastroenterology, neuropsychiatry, cardiac diabetes care etc.
Suven Life Sciences has reported total income of Rs. 3.97 crores during the period ended June 30, 2022
The company has reported total income of Rs. 186.97 crores during the period ended June 30, 2022.
Strand Life Sciences has sequenced a total of 12800 samples from July, 2021 to June, 2022, and identified more than a 100 lineages circulating in Bengaluru
Advancing to IND-enabling studies with multiple drug candidates
CEPI will provide seed funding of up to US$2.5 million to Codiak BioSciences.
An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.
Subscribe To Our Newsletter & Stay Updated
